Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and activity of GC1008 was evaluated in patients with advanced malignant melanoma and renal cell carcinoma. METHODS: In this multi-center phase I trial, cohorts of patients with previously treated malignant melanoma or renal cell carcinoma received intravenous GC1008 at 0.1, 0.3, 1, 3, 10, or 15 mg/kg on days 0, 28, 42, and 56. Patients achieving at least stable disease were eligible to receive Extended Treatment consisting of 4 doses of GC1008 every 2 weeks for up to 2 additional courses. Pharmacokinetic and exploratory biomarker assessments were performed. RESULTS: Twenty-nine patients, 28 with malignant melanoma and 1 with renal cell carcinoma, were enrolled and treated, 22 in the dose-escalation part and 7 in a safety cohort expansion. No dose-limiting toxicity was observed, and the maximum dose, 15 mg/kg, was determined to be safe. The development of reversible cutaneous keratoacanthomas/squamous-cell carcinomas (4 patients) and hyperkeratosis was the major adverse event observed. One malignant melanoma patient achieved a partial response, and six had stable disease with a median progression-free survival of 24 weeks for these 7 patients (range, 16.4-44.4 weeks). CONCLUSIONS: GC1008 had no dose-limiting toxicity up to 15 mg/kg. In patients with advanced malignant melanoma and renal cell carcinoma, multiple doses of GC1008 demonstrated acceptable safety and preliminary evidence of antitumor activity, warranting further studies of single agent and combination treatments. TRIAL REGISTRATION: Clinicaltrials.gov NCT00356460.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Fresolimumab, a human monoclonal antibody against TGF‐β in a phase 1 clinical trial (NCT00356460), demonstrated preliminary evidence of anti‐tumor activity in malignant melanoma and renal cell carcinoma [42].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 4×
“Recently, targeted therapies directed against B-RAF and other genes have been used successfully to treat patients with MM [33].”
BackgroundInfluentialMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335 · cited 1×
“Norton and Massague [48,49] have proposed that cancer cell migration and ‘‘re-seeding’’ of the primary tumor with cells primed for metastatic growth leads to a tumor with heterogenous subpopulations of aggressive, rapidly growing cancer cells that may become resistant to treatment.”
BackgroundRAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919 · cited 1×
“Transforming growth factor-beta (TGFb) is a pleiotropic cytokine that is a member of a superfamily of ligands that includes bone morphogenetic proteins and activins [1,2].”
BackgroundKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Self-citationTransforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452 · cited 2×
“With broad activity in natural killer (NK) cells, T cells including T regulatory cells, NKT cells, monocytes/ macrophages, and dendritic cells, TGFb can down-regulate both primary and secondary immune responses and suppress antitumor effector cells [3,11,12].”
BackgroundKano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611660104 · Cited by 410 · cited 1×
“Several mechanisms have been proposed to explain the improved efficacy with cytotoxic agents and include increased diffusion of chemotherapy and payload-containing particles such as liposomes into tumor masses [45,46], reversal of chemotherapy resistance [29,41], inhibition of DNA repair by blockade of cH2AX foci form…”
BackgroundEllenrieder, V., Hendler, S. F., Boeck, W., Seufferlein, T., Menke, A., Ruhland, C., Adler, G., & Gress, T. M. (2001) · PubMed · Cited by 361
Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116871 · Cited by 359 · cited 1×
“In a number of preclinical models, neutralizing antibodies or soluble receptors that bind TGFb have demonstrated antitumor activity [10,18–23].”
BackgroundIs cancer a disease of self-seeding?
Norton, L., & Massagué, J. (2006) · Nature Medicine · doi:10.1038/nm0806-875 · Cited by 346 · cited 1×
“Norton and Massague [48,49] have proposed that cancer cell migration and ‘‘re-seeding’’ of the primary tumor with cells primed for metastatic growth leads to a tumor with heterogenous subpopulations of aggressive, rapidly growing cancer cells that may become resistant to treatment.”
BackgroundBiswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L., & Arteaga, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30740 · Cited by 346
Wikström, P., Stattin, P., Franck-Lissbrant, I., Damber, J.-E., & Bergh, A. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980915)37:1<19::aid-pros4>3.0.co;2-3 · Cited by 307 · cited 1×
“Furthermore, elevated plasma TGFb levels correlate with advanced tumor stage, metastases, and poor survival [15–17].”
BackgroundKäkönen, S.-M., Selander, K. S., Chirgwin, J. M., Yin, J. J., Burns, S., Rankin, W. A., Grubbs, B. G., Dallas, M., Cui, Y., & Guise, T. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202561200 · Cited by 276
Immunoregulatory T cells in tumor immunity
Terabe, M., & Berzofsky, J. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.010 · Cited by 264 · cited 1×
“With broad activity in natural killer (NK) cells, T cells including T regulatory cells, NKT cells, monocytes/ macrophages, and dendritic cells, TGFb can down-regulate both primary and secondary immune responses and suppress antitumor effector cells [3,11,12].”
BackgroundSelf-citationTrachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R. W., Peters, H., Rota, S., Remuzzi, G., Rump, L. C., Sellin, L. K., et al. (2011) · Kidney International · doi:10.1038/ki.2011.33 · Cited by 263 · cited 2×
“GC1008 is being investigated as a treatment for cancer and fibrotic diseases [31].”
BackgroundMethodKobie, J. J., Wu, R. S., Kurt, R. A., Lou, S., Adelman, M. K., Whitesell, L. J., Ramanathapuram, L. V., Arteaga, C. L., & Akporiaye, E. T. (2003) · PubMed · Cited by 251
Bouquet, F., Pal, A., Pilones, K. A., Demaria, S., Hann, B., Akhurst, R. J., Babb, J. S., Lonning, S. M., DeWyngaert, J. K., Formenti, S. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0544 · Cited by 240
Nam, J.-S., Terabe, M., Mamura, M., Kang, M.-J., Chae, H., Stuelten, C., Kohn, E., Tang, B., Sabzevari, H., Anver, M. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0215 · Cited by 233
Self-citationBandyopadhyay, A., Wang, L., Agyin, J., Tang, Y., Lin, S., Yeh, I.-T., De, K., & Sun, L.-Z. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010365 · Cited by 204 · cited 1×
“A variety of anti-TGFb agents combined with chemotherapy, radiation, biologics, immunotherapeutics and vaccines have demonstrated enhanced antitumor effects in preclinical models [11,21,22,25,28– 30,41–44].”
BackgroundSwitching TGFβ from a tumor suppressor to a tumor promoter
Inman, G. J. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.12.004 · Cited by 197
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
Arnault, J. P., Wechsler, J., Escudier, B., Spatz, A., Tomasic, G., Sibaud, V., Aractingi, S., Grange, J.-D., Poirier-Colame, V., Malka, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4823 · Cited by 169 · cited 1×
“Interestingly, KAs and SCCs have been reported in patients receiving sorafenib, B-RAF inhibitors, and anti-tumor necrosis factor (TNF) a-directed therapies [33,38,39], and recent data with vemurafemib have implicated RAS pathway mutations and signaling through the mitogen-activated protein kinase pathway in the develo…”
BackgroundGanapathy, V., Ge, R., Grazioli, A., Xie, W., Banach-Petrosky, W., Kang, Y., Lonning, S., McPherson, J., Yingling, J. M., Biswas, S., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-122 · Cited by 168
Goudie, D. R., D’Alessandro, M., Merriman, B., Lee, H., Szeverényi, I., Avery, S., O’Connor, B. D., Nelson, S. F., Coats, S. E., Stewart, A., et al. (2011) · Nature Genetics · doi:10.1038/ng.780 · Cited by 157 · cited 11×
“Notable safety observations included a variety of treatmentemergent skin lesions including hyperkeratosis and eruptive KA/ SCCs. KAs are epidermal tumors characterized by initially rapid growth typically followed by spontaneous resolution [35].”
BackgroundInfluentialReversal of Tumor-induced Immunosuppression by TGF-β Inhibitors
Wojtowicz‐Praga, S. (2003) · Investigational New Drugs · doi:10.1023/a:1022951824806 · Cited by 146 · cited 1×
“Increased TGFb expression has been reported in many different malignancies including prostate, breast, lung, pancreatic, renal cell, liver, colon, gastric, esophageal, ovarian, cervical, bladder, thyroid, head and neck cancers, melanoma, gliomas, and multiple myeloma [13,14].”
BackgroundRodeck, U., Bossler, A., Graeven, U., Fox, F. E., Nowell̀, P. C., Knabbe, C., & Kari, C. (1994) · PubMed · Cited by 144
Activity of paclitaxel liposome formulations against human ovarian tumor xenografts
Sharma, A., Mayhew, E. G., Bolcsak, L. E., Cavanaugh, C., Harmon, P. A., Janoff, A. S., & Bernacki, R. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970328)71:1 · Cited by 136
Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?
Tan, A. R., Alexe, G., & Reiss, M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0184-1 · Cited by 124 · cited 5×
“Remodeling of the tumor stroma occurs through the induction of vascular endothelial growth factor (VEGF) and angiogenesis, dysregulated lymphangiogenesis, increased extracellular matrix deposition, and production of factors such as parathyroid hormone-related peptide (PTHrP) that increase osteoclastic activity [4,8–10…”
BackgroundInfluentialSelf-citationUeda, R., Fujita, M., Zhu, X., Sasaki, K., Kastenhuber, E. R., Kohanbash, G., McDonald, H. A., Harper, J., Lonning, S., & Okada, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1067 · Cited by 117 · cited 1×
“In a number of preclinical models, neutralizing antibodies or soluble receptors that bind TGFb have demonstrated antitumor activity [10,18–23].”
BackgroundTerabe, M., Ambrosino, E., Takaku, S., O'Konek, J. J., Venzon, D., Lonning, S., McPherson, J. M., & Berzofsky, J. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1066 · Cited by 112 · cited 2×
“A variety of anti-TGFb agents combined with chemotherapy, radiation, biologics, immunotherapeutics and vaccines have demonstrated enhanced antitumor effects in preclinical models [11,21,22,25,28– 30,41–44].”
BackgroundSelf-citationCaulı́n, C., Scholl, F. G., Frontelo, P., Gamallo, C., & Quintanilla, M. (1995) · PubMed · Cited by 105
Keratoacanthoma: a tumor in search of a classification
Karaa, A., & Khachemoune, A. (2007) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2007.03260.x · Cited by 103 · cited 7×
“Notable safety observations included a variety of treatmentemergent skin lesions including hyperkeratosis and eruptive KA/ SCCs. KAs are epidermal tumors characterized by initially rapid growth typically followed by spontaneous resolution [35].”
BackgroundInfluentialOhmori, T., Yang, J.-L., Price, J. O., & Arteaga, C. L. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4261 · Cited by 98 · cited 2×
“A variety of anti-TGFb agents combined with chemotherapy, radiation, biologics, immunotherapeutics and vaccines have demonstrated enhanced antitumor effects in preclinical models [11,21,22,25,28– 30,41–44].”
BackgroundBiswas, S., Nyman, J. S., Alvarez, J., Chakrabarti, A., Ayres, A., Sterling, J., Edwards, J., Rana, T., Johnson, R., Perrien, D. S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027090 · Cited by 93
Esser, A. C., Abril, A., Fayne, S., & Doyle, J. A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.044 · Cited by 80 · cited 1×
“Interestingly, KAs and SCCs have been reported in patients receiving sorafenib, B-RAF inhibitors, and anti-tumor necrosis factor (TNF) a-directed therapies [33,38,39], and recent data with vemurafemib have implicated RAS pathway mutations and signaling through the mitogen-activated protein kinase pathway in the develo…”
BackgroundElevated plasma TGF-β1 levels correlate with decreased survival of metastatic breast cancer patients
Ivanović, V., Demajo, M., Krtolica, K., Krajnović, M., Konstantinović, M. M., Baltić, V., Prtenjak, G., Stojiljković, B., Breberina, M., Nešković‐Konstantinović, Z., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.02.027 · Cited by 79 · cited 1×
“Furthermore, elevated plasma TGFb levels correlate with advanced tumor stage, metastases, and poor survival [15–17].”
BackgroundTabe, Y., Shi, Y. X., Zeng, Z., Jin, L., Shikami, M., Hatanaka, Y., Miida, T., Hsu, F. J., Andreeff, M., & Konopleva, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062785 · Cited by 78
Self-citationLiao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2429 · Cited by 73 · cited 3×
“Remodeling of the tumor stroma occurs through the induction of vascular endothelial growth factor (VEGF) and angiogenesis, dysregulated lymphangiogenesis, increased extracellular matrix deposition, and production of factors such as parathyroid hormone-related peptide (PTHrP) that increase osteoclastic activity [4,8–10…”
BackgroundWojtowicz-Praga, S., Verma, U. M., Wakefield, L., Esteban, J. M., Hartmann, D., & Mazumder, A. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199605000-00001 · Cited by 60
Transforming growth factor-β in in vivo resistance
Teicher, B. A., Holden, S. A., Ara, G., & Chen, G. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050435 · Cited by 59
Putti, T. C., Teh, M., & Lee, Y. S. (2004) · Modern Pathology · doi:10.1038/modpathol.3800063 · Cited by 54 · cited 5×
“Notable safety observations included a variety of treatmentemergent skin lesions including hyperkeratosis and eruptive KA/ SCCs. KAs are epidermal tumors characterized by initially rapid growth typically followed by spontaneous resolution [35].”
BackgroundInfluentialReversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin
Teicher, B. A., Maehara, Y., Kakeh, Y., Ara, G., Keyes, S. R., Wong, J. S., & Herbst, R. S. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970328)71:1<49::aid-ijc10>3.0.co;2-4 · Cited by 52 · cited 2×
“A variety of anti-TGFb agents combined with chemotherapy, radiation, biologics, immunotherapeutics and vaccines have demonstrated enhanced antitumor effects in preclinical models [11,21,22,25,28– 30,41–44].”
BackgroundWunderlich, H., Steiner, T., Kosmehl, H., Junker, U., Reinhold, D., Reichelt, O., Zermann, D.-H., & Schubert, J. (1998) · Urologia Internationalis · doi:10.1159/000030255 · Cited by 44
Taniguchi, Y., Kawano, K., Minowa, T., Sugino, T., Shimojo, Y., & Maitani, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01646.x · Cited by 25
Harper, J. W., Green, T. L., Munroe, K. J., Manning, C. M., Tao, J., Simon, K., Wakefield, L. M., Hsu, F. J., McPherson, J. D., Kaplan, J. M., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-3826 · Cited by 2
Self-citationMunroe, K. J., Manning, C. M., Green, T. L., Tao, J., Simon, K., McPherson, J. M., Kaplan, J. M., Pinkas, J., O'Brien, M., Gregory, R. C., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b244 · Cited by 1
Zhou, Y., Tabe, Y., Jin, L., Miida, T., Zeng, Z., Andreeff, M., & Konopleva, M. Y. (2010) · Blood · doi:10.1182/blood.v116.21.1814.1814 · Cited by 1
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142
“Another TGF-β monoclonal antibody, Fresolimumab (GC-1008), was demonstrated to be safe and well tolerated in Phase I and Phase II trials [261].”
Metadata
- Authors
- Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P.
- Affiliations
- National Cancer Institute (US)
- Rutgers Cancer Institute (US)
- The Ohio State University (US)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Morris, John C.
- Berzofsky, Jay A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-11
- Volume
- 9
- Issue
- 3
- Pages
- e90353
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3949712
- OpenAlex
- W2075873658
- Cited by
- 487
- References
- 50
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 48 · 2023: 47 · 2022: 36 · 2021: 46 · 2020: 49 · 2019: 30 · 2018: 29 · 2017: 41 · 2016: 30 · 2015: 29 · 2014: 9
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Massachusetts General Hospital
- Ohio State University
- Rutgers Cancer Institute of New Jersey
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- TGF-beta, melanoma, renal cell carcinoma, advanced cancer, dose escalation, safety, pharmacokinetics, keratoacanthoma, squamous cell carcinoma, anticancer activity, progression-free survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Staging, Tomography, X-Ray Computed, Transforming Growth Factor beta, Treatment Outcome, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.